FindTrial
Sign In

Evidence Synthesis, Practice Guidelines and Real-World Prescriptions of New Generation Antidepressants in the Treatment of Depression

Evidence Synthesis, Practice Guidelines and Real-World Prescriptions of New Generation Antidepressants in the Treatment of Depression - Evidence Synthesis, Practice Guidelines and Real-World Prescriptions of New Generation Antidepressants in the Treatment of Depression

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000031898
Enrollment
1000
Registered
2018-04-01
Start date
2018-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major depressive disorder

Interventions

None listed

Sponsors

Department of Health Promotion and Human Behavior, School of Public Health, Kyoto University Graduate School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with major depressive disorder, adults, both sex.

Exclusion criteria

Exclusion criteria: Patients with bipolar disorder and psychotic depression.

Design outcomes

Primary

MeasureTime frame
Ranking of antidepressants based on efficacy and acceptability by means of cumulative network meta-analysis. Ranking of recommended antidepressants in main guidelines in America and Europe. Ranking of real-world prescription of antidepressants based on American database MEPS.—

Countries

Japan,North America,Europe

Contacts

Public ContactYan Luo

Kyoto University Graduate School of Medicine Department of Health Promotion and Human Behavior, School of Public Health

lilacluo@gmail.com+81-75-753-9491

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026